User:Mr. Ibrahem/Remdesivir

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Remdesivir
Clinical data
Pronunciation/rɛmˈdɛsɪvɪər/ rem-DESS-i-veer
Trade namesVeklury
Other namesGS-5734
AHFS/Drugs.comMonograph
MedlinePlusa620033
License data
Pregnancy
category
Routes of
administration		Intravenous
Legal status
Legal status
Identifiers
  • (2S)-2-{(2R,3S,4R,5R)-[5-(4-Aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxy-tetrahydro-furan-2-ylmethoxy]phenoxy-(S)-phosphorylamino}propionic acid 2-ethyl-butyl ester
Chemical and physical data
FormulaC27H35N6O8P
Molar mass602.585 g·mol−1
3D model (JSmol)
  • CCC(COC(=O)[C@@H](NP(=O)(Oc1ccccc1)OC[C@H]1O[C@@]([C@@H]([C@@H]1O)O)(C#N)c1ccc2n1ncnc2N)C)CC
  • InChI=1S/C27H35N6O8P/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31)/t17-,21+,23+,24+,27-,42-/m0/s1
  • Key:RWWYLEGWBNMMLJ-YSOARWBDSA-N

Remdesivir, sold under the brand name Veklury, is a antiviral medication which has been used for COVID‑19 in those who require oxygen therapy or are at high risk.[9][8] In November of 2020 the World Health Organization conditionally recommendation against its use for COVID-19, regardless of disease severity.[11] It is given by injection into a vein for 3 to 10 days.[9][12]

Common side effects include increased liver enzymes and nausea.[9] Other side effects may include allergic reactions.[10] It is unclear if use during pregnancy is safe; though breastfeeding appears okay.[13] Remdesivir is converted by the body into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase.[14]

Remdesivir was approved for medical use in Europe in July 2020 and the United States in October 2020.[8][15] It was developed by Gilead Sciences and was originally studied for hepatitis C, Ebola, and Marburg infections.[16][17] In the United States it costs about 2,600 USD for five days as of 2021.[18] This amount in the UK costs about £2,040.[19]

References[edit]

  1. ^ a b "Veklury Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 13 July 2020. Retrieved 16 August 2020.
  2. ^ "Summary for ARTG Entry:338419 Veklury remdesivir 100 mg powder for injection vial". Therapeutic Goods Administration (TGA). Retrieved 16 August 2020.
  3. ^ "Veklury Product information". Health Canada. 25 April 2012. Retrieved 22 October 2020.
  4. ^ "Veklury 100 mg concentrate for solution for infusion – Summary of Product Characteristics (SmPC)". (emc). 6 July 2020. Retrieved 4 October 2020.
  5. ^ "Veklury 100 mg powder for concentrate for solution for infusion – Summary of Product Characteristics (SmPC)". (emc). Retrieved 4 October 2020.
  6. ^ "Remdesivir injection Remdesivir injection, powder, lyophilized, for solution". DailyMed. 1 September 2020. Retrieved 25 September 2020.
  7. ^ "FDA Approves First Treatment for COVID-19". U.S. Food and Drug Administration (FDA) (Press release). 22 October 2020. Retrieved 22 October 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  8. ^ a b c "Veklury EPAR". European Medicines Agency (EMA). 23 June 2020. Retrieved 6 July 2020.
  9. ^ a b c d e "Remdesivir Monograph for Professionals". Drugs.com. Retrieved 13 July 2021.
  10. ^ a b "Fact Sheet for Patients And Parent/Caregivers Emergency Use Authorization (EUA) Of Remdesivir For Coronavirus Disease 2019 (COVID-19)" (PDF). U.S. Food and Drug Administration (FDA). Retrieved 8 May 2020.
  11. ^ World Health Organization (2020). Therapeutics and COVID-19: living guideline, 20 November 2020. World Health Organization (WHO) (Report). hdl:10665/336729. WHO/2019-nCov/remdesivir/2020.1.
  12. ^ "Statement on Therapies for High-Risk, Nonhospitalized Patients". COVID-19 Treatment Guidelines. Retrieved 7 January 2022.
  13. ^ "Remdesivir (Veklury) Use During Pregnancy". Drugs.com. Retrieved 13 July 2021.
  14. ^ Yan VC, Muller FL (14 May 2020). "Gilead should ditch remdesivir and focus on its simpler and safer ancestor". Stat. Boston Globe Media Partners.
  15. ^ "New Drug Therapy Approvals 2020". U.S. Food and Drug Administration (FDA). 31 December 2020. Retrieved 17 January 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  16. ^ Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, et al. (April 2020). "Current pharmacological treatments for COVID-19: What's next?". British Journal of Pharmacology. 177 (21): 4813–4824. doi:10.1111/bph.15072. eISSN 1476-5381. PMC 7264618. PMID 32329520.
  17. ^ Stephens B (18 April 2020). "The Story of Remdesivir". The New York Times. p. A23. Retrieved 11 May 2020.
  18. ^ Chamary, J. V. "The Strange Story Of Remdesivir, A Covid Drug That Doesn't Work". Forbes. Retrieved 13 July 2021.
  19. ^ "6.1. Coronavirus". British National Formulary (BNF) (82 ed.). BMJ Group and the Pharmaceutical Press. September 2021 – March 2022. pp. 665–667. ISBN 978-0-85711-413-6.{{cite book}}: CS1 maint: date format (link)
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Remdesivir&oldid=1066190063"